IDH2 and acute myeloid leukemia: Interestingly, during the same meeting other groups reported that patients receiving CPX-351 achieved a 100% of response if IDH2-mutated [17], and Chiche et al. assessed that the favorable outcome was observed in patients after HSCT and CPX-351 erased the poor prognosis associated with unfavorable mutations [18], thus making CPX-351 an attracting therapeutic chance for this subgroup of AML patients.